STOCK TITAN

Awakn Life Scien - AWKNF STOCK NEWS

Welcome to our dedicated page for Awakn Life Scien news (Ticker: AWKNF), a resource for investors and traders seeking the latest updates and insights on Awakn Life Scien stock.

Overview of Awakn Life Sciences Corp.

Awakn Life Sciences Corp. (symbol: AWKNF) is a clinical-stage biotechnology company at the forefront of developing innovative medication-assisted therapies for addiction, with a particular focus on Alcohol Use Disorder (AUD) and other substance use and mental health disorders. With a robust pipeline of research and development programs, Awakn is dedicated to addressing significant unmet clinical needs in the field, combining breakthrough science with strategic collaborations across global markets.

Core Business and Therapeutic Focus

The company primarily concentrates on the development of novel therapeutic platforms that integrate pharmacological interventions with structured psychosocial support. Its flagship programs include:

  • AWKN-001: An investigational treatment that employs an N-methyl-D-aspartate receptor-modulating drug delivered intravenously in combination with manualized relapse prevention cognitive behavioral therapy (CBT) for severe AUD.
  • AWKN-002: A proprietary oral thin film formulation of esketamine designed for sublingual and buccal delivery, which is combined with structured alcohol education to target moderate to severe AUD.
  • Aminoindane/Serotonin-Dopamine Modulators (AWKN-SND-14): A new chemical entity series aimed at trauma-related mental health disorders, including Post-Traumatic Stress Disorder (PTSD), emphasizing improved safety profiles and enhanced clinical outcomes.

Research and Development Excellence

Awakn Life Sciences embodies a deep commitment to scientific rigor and innovation. The company consistently advances its R&D pipeline through strategic preclinical and clinical studies. Collaborations with globally recognized institutions such as Graft Polymer and the University of Nottingham have enabled the company to harness advanced drug delivery technologies and cutting-edge pharmacological testing. This collaborative approach not only bolsters its research capacity but also reinforces its credibility as an expert in biomedical innovation.

Strategic Collaborations and Global Partnerships

The company has forged notable partnerships that drive its research programs and enhance its therapeutic prospects. These include cooperative agreements with industry leaders specializing in drug delivery systems, as well as academic partnerships for preclinical and clinical evaluations. Such collaborations facilitate access to international capital markets, enable the use of state-of-the-art technologies, and underscore the company’s commitment to achieving transformative milestones in the treatment of addiction and mental health disorders.

Market Position and Industry Significance

In an industry marked by complex regulatory pathways and rapidly evolving scientific landscapes, Awakn Life Sciences distinguishes itself through its integrated therapeutic strategies and cross-disciplinary expertise. The company addresses a crucial gap in current treatment paradigms for conditions like AUD, where existing standards of care are often inadequate. By pioneering medication-assisted treatments that combine innovative drug formulations with cognitive therapies, Awakn aims to reshape treatment protocols and improve patient outcomes.

Expertise, Experience, and Regulatory Alignment

Awakn Life Sciences leverages its clinical expertise and collaborative framework to navigate key regulatory channels. Its proactive engagement with regulatory authorities, including successful milestones such as pre-IND meetings with bodies like the U.S. FDA, reinforces its authority and commitment to meeting stringent industry standards. The comprehensive nature of its R&D efforts, combined with transparent communication of its research approach, ensures that information provided remains credible and enduringly relevant.

Conclusion

Overall, Awakn Life Sciences Corp. represents a compelling model of innovation within the biotechnology sector. Through its focus on breakthrough therapeutics for addiction and mental health disorders, it combines strategic scientific research with robust industry partnerships. This deep commitment to advancing safe and effective treatment options positions the company as a key influencer in transforming therapeutic landscapes. Investors and analysts can gain valuable insights by examining the company’s methodical approach to drug development, its strategic market positioning, and its emphasis on regulatory compliance and scientific excellence.

Rhea-AI Summary
Awakn Life Sciences Corp. is set to list its common shares on the Canadian Securities Exchange (CSE) after receiving conditional approval, with the intention to delist from Cboe Canada. The company has also closed the fifth tranche of a non-brokered private placement financing, issuing 142,857 units for gross proceeds of $65,714 for this tranche and $3,030,377 in total for the Offering to date.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
-
Rhea-AI Summary
Awakn Life Sciences Corp. has designated program AWKN-002 for Alcohol Use Disorders in the US market, focusing on a proprietary S-ketamine formulation administered sublingually via an oral thin film. The company has successfully completed an investigative study on the dissociative effect and reduction in alcohol cravings of the S-ketamine OTF, leading to the designation of AWKN-002. Additionally, Awakn has signed a global licensing agreement with LTS Lohmann Therapie-Systeme AG for a proprietary S-ketamine OTF, ensuring strong intellectual property protection and potential to rapidly progress to late clinical stage trials.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-29.17%
Tags
none
-
Rhea-AI Summary
Awakn Life Sciences Corp. (NEO: AWKN) (OTCQB: AWKNF) (FSE: 954) announces global licensing agreement with LTS Lohmann Therapie-Systeme AG for a proprietary S-ketamine formulation to treat addiction, anxiety, and eating disorders. The agreement includes exclusive rights, access to Phase 1 data, and patents filed in the US and key international markets. The sublingual S-ketamine formulation offers potential advancements in addiction treatment, with faster onset of action, precise dosing, and reduced adverse effects. The agreement also includes terms related to milestone payments, royalties, and commercial manufacturing of the drug product by LTS.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.38%
Tags
none
Rhea-AI Summary
Awakn Life Sciences Corp. (NEO: AWKN) (OTCQB: AWKNF) (FSE: 954) announces recent corporate updates, including regulatory approval for a phase III clinical trial for its lead program AWKN-P001 for the treatment of Severe Alcohol Use Disorder, completion of a feasibility study for its proprietary formulation of MDMA, and engagement with Orphan Insight Ltd. to develop market access for its lead program. The company also closed the fourth tranche of a private placement financing for gross proceeds of $230,000 and $2,964,663 in total for the Offering to date.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
-
Rhea-AI Summary
Awakn Life Sciences Corp. (NEO: AWKN) (OTCQB: AWKNF) (FSE: 954) announces clinical trial authorization from the MHRA and ethical approval from the Health Research Authority in the UK for a phase III clinical trial for its lead program AWKN-P001, a N-methyl-D-aspartate receptor-modulating drug used in combination with psycho-social support to treat Severe Alcohol Use Disorder (SAUD). The trial will be funded by Awakn, The University of Exeter, and a partnership between the NIHR and the MRC. Enrollment for the phase III is due to start in Q1 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-6.67%
Tags
-
Rhea-AI Summary
Awakn Life Sciences Corp. (NEO: AWKN) (OTCQB: AWKNF) (FSE: 954) receives notice of non-compliance from Cboe Canada regarding its common stock listing, with 90 days to address the issue. The notice does not impact the company's operations or its focus on advancing psychedelic research and development.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-48.91%
Tags
none
Rhea-AI Summary
Awakn Life Sciences has engaged Orphan Insight to develop market access, pricing, and reimbursement for its lead program AWKN-P001, which targets Severe Alcohol Use Disorder (SAUD). AWKN-P001 achieved positive results in a phase II study, with 86% abstinence in the 6 months post-treatment and a 50% reduction in Heavy Drinking Days (HDD) versus placebo. Awakn has received an Innovation Passport from the UK Medicines and Healthcare products Regulatory Agency (MHRA) and has submitted a Clinical Trial Application (CTA) for a phase III trial of AWKN-P001 in the UK. The trial will be run by Awakn, The University of Exeter, and a partnership between NIHR and the MRC, and will be delivered across ten NHS sites.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-10.9%
Tags
none
-
Rhea-AI Summary
Awakn Life Sciences completes feasibility study confirming stability of MDMA on Catalent's Zydis ODT technology, potentially improving performance and benefiting patients compared to oral capsules.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
5.8%
Tags
none
-
Rhea-AI Summary
Awakn Life Sciences Corp. announces closing of third tranche of private placement and provides corporate update on recent progress.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.11%
Tags
none
Rhea-AI Summary
Awakn submits Clinical Trial Application for phase III trial of AWKN-P001 for Severe Alcohol Use Disorder (SAUD)
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-9.3%
Tags

FAQ

What is the current stock price of Awakn Life Scien (AWKNF)?

The current stock price of Awakn Life Scien (AWKNF) is $0.065 as of February 7, 2025.

What is the market cap of Awakn Life Scien (AWKNF)?

The market cap of Awakn Life Scien (AWKNF) is approximately 2.7M.

What is the core focus of Awakn Life Sciences Corp.?

Awakn Life Sciences Corp. is dedicated to developing innovative medication-assisted therapies for addiction, with a primary focus on Alcohol Use Disorder (AUD) and trauma-related mental health disorders.

What are the main research and development programs at Awakn?

The company is advancing multiple R&D programs, including AWKN-001 for severe AUD, AWKN-002 for moderate to severe AUD using an oral thin film formulation, and a novel aminoindane series aimed at addressing PTSD and related conditions.

How does Awakn integrate therapy in its treatment approach?

Awakn combines pharmacological interventions with structured psychosocial support such as cognitive behavioral therapy, ensuring a holistic approach to treating addiction and improving patient outcomes.

What strategic partnerships does the company maintain?

Awakn has established key collaborations with industry specialists and academic institutions, including partnerships with Graft Polymer and the University of Nottingham, to leverage advanced drug delivery systems and enhance clinical research.

How does the company ensure regulatory compliance?

The company engages proactively with regulatory bodies, as seen in its pre-IND meetings with the FDA, and follows stringent clinical research protocols to ensure its therapeutic developments meet current industry standards.

What significance does Awakn hold in the biotechnology market?

By addressing critical unmet needs in addiction treatment and mental health, Awakn positions itself as a scientifically driven company that combines innovative drug formulations with strategic collaborations, setting a benchmark in the biopharmaceutical industry.

Which therapeutic areas are prioritized in the company’s pipeline?

The company prioritizes treatments for Alcohol Use Disorder, other forms of substance abuse, and trauma-related mental health disorders such as PTSD, aiming to offer breakthrough and comprehensive therapeutic options.
Awakn Life Scien

OTC:AWKNF

AWKNF Rankings

AWKNF Stock Data

2.74M
36.00M
10.23%
5.77%
Biotechnology
Healthcare
Link
Canada
Toronto